A new study has received a $74.5 million NIH grant to test Alzheimer's prevention strategies in a Colombian kindred with a genetic mutation causing early-onset Alzheimer's disease.
Roche has ended its collaboration with UCB, relinquishing rights to bepranemab, a Phase 2a Alzheimer's candidate, marking the second Alzheimer's partnership termination this year.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.